Gonorrhea: Market View
Summary
This report provides a data-driven overview of the current and future competitive landscape in Gonorrhea Therapeutics.- In 2025, there were more than 2.75 million diagnosed incident cases of GC in the 16 countries covered in the analyst’s epidemiology forecast.
- The GC market remains largely generic, with approved treatments spanning several antibiotic classes including penicillin antibiotics, sulfonamides, fluoroquinolones, tetracyclines, azalide derivatives, aminopenicillins, and macrolides.
- Treatment has evolved from fluoroquinolone monotherapy to ceftriaxone-azithromycin dual therapy and, since 2020, ceftriaxone 500 mg IM monotherapy, which remains the recommended first-line treatment in 2026.
- Newly approved oral agents GSK’s Blujepa (gepotidacin) and Innoviva’s Nuzolvence (zoliflodacin) expand options and may help address AMR, but are currently limited to uncomplicated urogenital GC.
- The GC pipeline holds 42 molecules with no assets in the Pre-registration and Phase II stages, two assets in Phase III development, and three assets in Phase I development.
- Over the past decade, 404 clinical trials have been conducted in GC. The year with the most studies initiated was 2018, with 75 trials, followed by 2021.
- Over the past 10 years, acquisitions dominated GC product deals in South America (100.0%), Asia-Pacific (56.4%), Europe (41.5%), North America (37.8%), and the Middle East and Africa (27.3%). Licensing was most common in the Middle East and Africa (36.4%), while mergers were concentrated in North America (13.3%), Asia-Pacific (6.4%), and Europe (3.8%); none were recorded in South America or the Middle East and Africa.
- Key opinion leaders agree that expanded screening has shifted gonorrhea diagnoses toward asymptomatic disease, creating persistent diagnosis-to-treatment delays across care settings. While ceftriaxone remains trusted for high cure rates (95-98%), its intramuscular administration severely limits treatment convenience, and existing oral alternatives provide inadequate efficacy and coverage.
- Consequently, clinicians emphasize an urgent need for an affordable, single-dose oral regimen delivering at least 95% efficacy across all anatomical sites to outrun inevitable antimicrobial resistance. Beyond therapeutics, experts identify rapid, resistance-predicting point-of-care diagnostics and effective partner treatment as critical structural priorities to prevent reinfection and curb transmission.
Scope
The analyst’s Gonorrhea: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule type
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Gonorrhea Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Reflux Esophagitis (Gastroesophageal Reflux Disease)Therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

